53732
document
The influence of penbutolol and placebo on blood sugar levels and insulin consumption in the glucose-controlled insulin infusion system ( " artificial endocrine pancreas " ) . The aim of the study was to investigate the influence of 40 mg of the beta-blocker penbutolol ( Betapressin TM ; Hoechst Ltd. , Frankfurt/Main ) in comparison to placebo on the insulin consumption on the blood sugar profile in twelve insulin-dependent diabetes ( IDDM ) patients . The patients were treated with penbutolol and placebo for a period of three days , and then were examined with the help of the glucose-controlled insulin infusion system . The blood sugar profile and insulin consumption over a 24 hour period was not affected by either penbutolol or placebo , nor could any changes be measured in these parameters when measured after food intake . After a submaximal exercise load on the bicycle ergometer ( 1 watt per kg body weight ) following an evening meal , no difference could be observed between penbutolol and placebo in the above-mentioned parameters . The same was also true for hormonal parameters as STH , ACTH , cortisol , and catecholamines . These findings demonstrated that medication of penbutolol over a three-day period has no influence on the baseline blood sugar profile and insulin consumption or on insulin consumption after food intake during rest and physical exercise .
53733
Intervention_Pharmacological
penbutolol
53734
Intervention_Control
placebo
53735
Intervention_Pharmacological
penbutolol
53736
Intervention_Control
placebo
53737
Intervention_Pharmacological
penbutolol
53738
Intervention_Control
placebo
53739
Intervention_Physical
glucose-controlled insulin infusion system
53740
Outcome_Physical
blood sugar profile
53741
Outcome_Physical
insulin consumption
53742
Outcome_Physical
STH , ACTH , cortisol , and catecholamines